Niraparib Extends Time Without Symptoms in Ovarian Cancer

FRIDAY, March 22, 2019 -- Women with recurrent ovarian cancer who receive the poly ADP ribose polymerase (PARP) inhibitor niraparib as maintenance therapy after treatment have both more time without side effects and significantly longer...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news